Chemotherapy

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 3, 2010, Pages 408-412

  Ikeda, Masafumi ^a   Nakachi, Kohei ^a   Mitsunaga, Shuichi ^a   Ueno, Hideki ^b   Morizane, Chigusa ^b   Kondo, Shunsuke ^b   Okusaka, Takuji ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Intra arterial chemotherapy; Sorafenib

Indexed keywords

CISPLATIN; FLUOROURACIL; INTERFERON; PLACEBO; SORAFENIB;

ABLATION THERAPY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CHEMOEMBOLIZATION; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 79960755441     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
2. Cheng A, Kang Y, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
3. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
4. Zhu AX: Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112: 250-259, 2008.
5. Furuse J: Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol 67: 8-15, 2008.
6. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006. (Pubitemid 46630787)
7. Furuse J, Ishii H, Nakachi K, et al: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99: 159-165, 2008. (Pubitemid 350239045)
8. Kajanti M, Pyrhönen S, Mäntylä M, et al: Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol 15: 37-40, 1992.
9. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, et al: Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 46: 1122-1125, 1999. (Pubitemid 29224804)